Iterum Therapeutics plc (ITRM)
Market Cap | 18.96M |
Revenue (ttm) | n/a |
Net Income (ttm) | -35.58M |
Shares Out | 16.55M |
EPS (ttm) | -2.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 269,452 |
Open | 1.230 |
Previous Close | 1.200 |
Day's Range | 1.080 - 1.260 |
52-Week Range | 0.622 - 2.500 |
Beta | 2.28 |
Analysts | Strong Buy |
Price Target | 6.00 (+422.19%) |
Earnings Date | Aug 9, 2024 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ITRM stock is "Strong Buy" and the 12-month stock price forecast is $6.0.
News
![](https://cdn.snapi.dev/images/v1/7/x/press17-2489877.jpg)
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
![](https://cdn.snapi.dev/images/v1/i/m/press3-2455926.jpg)
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024
![](https://cdn.snapi.dev/images/v1/d/f/press18-2426517.jpg)
Iterum Therapeutics Reports First Quarter 2024 Financial Results
- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval--
![](https://cdn.snapi.dev/images/v1/j/d/conf12-2411742.jpg)
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...
![](https://cdn.snapi.dev/images/v1/f/j/press9-2396813.jpg)
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024--
![](https://cdn.snapi.dev/images/v1/1/g/press12-2345729.jpg)
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- -Resubmission of NDA On Track for Early Q2 24— - -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Irela...
![](https://cdn.snapi.dev/images/v1/l/o/conf5-2336359.jpg)
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
![](https://cdn.snapi.dev/images/v1/n/4/press16-2326295.jpg)
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral anti...
![](https://cdn.snapi.dev/images/v1/c/w/press1-2250311.jpg)
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority to Augmentin ® ; Demonstrated Statistical Superiority Re-submission of NDA to FDA Expected in Q2 2024 Potential to be First Oral Penem Ap...
![](https://cdn.snapi.dev/images/v1/k/b/press18-2181722.jpg)
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation ora...
![](https://cdn.snapi.dev/images/v1/p/v/press3-2156379.jpg)
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024- - DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Ther...
![](https://cdn.snapi.dev/images/v1/q/b/conf14-2143895.jpg)
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
![](https://cdn.snapi.dev/images/v1/r/w/conf4-2100759.jpg)
Iterum Therapeutics to Present Data at IDWeek 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
![](https://cdn.snapi.dev/images/v1/g/j/press4-2019183.jpg)
Iterum Therapeutics Reports Second Quarter 2023 Financial Results
-- Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 -- -- Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (N...
![](https://cdn.snapi.dev/images/v1/r/e/conf14-2008227.jpg)
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
![](https://cdn.snapi.dev/images/v1/6/0/conf12-1931100.jpg)
Iterum Therapeutics to Present Data at ASM Microbe 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
![](https://cdn.snapi.dev/images/v1/u/c/press8-1887140.jpg)
Iterum Therapeutics Reports First Quarter 2023 Financial Results
--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a cli...
![](https://cdn.snapi.dev/images/v1/7/2/press4-1847179.jpg)
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
![](https://cdn.snapi.dev/images/v1/e/r/press8-1799657.jpg)
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- -Registration Trial for uUTI Ongoing and On Track- - - -Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET--
![](https://cdn.snapi.dev/images/v1/c/w/conf18-1790601.jpg)
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
![](https://cdn.snapi.dev/images/v1/a/i/press20-1705223.jpg)
Iterum Therapeutics Reports Employment Inducement Grant
DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage pharmaceutical company focused on developing next genera...
![](https://cdn.snapi.dev/images/v1/y/f/press16-1676611.jpg)
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
DUBLIN, Ireland and CHICAGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next ge...
![](https://cdn.snapi.dev/images/v1/x/b/press2-1629703.jpg)
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
--Patient Enrollment in Registration Trial for uUTI Underway-- --Cash Runway into 2024--
![](https://cdn.snapi.dev/images/v1/5/g/press7-1590826.jpg)
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic approved for uncomplicated urinary tract infections in over 25 years--
![](https://cdn.snapi.dev/images/v1/9/b/conf18-1585975.jpg)
Iterum Therapeutics to Present Data at IDWeek 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...